Analysts Set Expectations for Astrazeneca FY2026 Earnings

Astrazeneca Plc (NYSE:AZN) – Stock analysts at Erste Group Bank increased their FY2026 earnings per share (EPS) estimates for shares of Astrazeneca in a report issued on Friday, June 5th. Erste Group Bank analyst H. Engel now forecasts that the company will post earnings per share of $10.30 for the year, up from their prior forecast of $10.17. The consensus estimate for Astrazeneca’s current full-year earnings is $9.39 per share.

Astrazeneca (NYSE:AZN) last posted its quarterly earnings data on Wednesday, April 29th. The company reported $2.58 earnings per share for the quarter, beating analysts’ consensus estimates of $2.52 by $0.06. Astrazeneca had a return on equity of 30.86% and a net margin of 17.19%.The company had revenue of $15.29 billion during the quarter, compared to analyst estimates of $14.93 billion.

A number of other analysts have also commented on the company. Deutsche Bank Aktiengesellschaft reissued a “sell” rating on shares of Astrazeneca in a report on Tuesday, June 9th. Jefferies Financial Group reissued a “buy” rating on shares of Astrazeneca in a research report on Tuesday, June 9th. Weiss Ratings restated a “buy (b)” rating on shares of Astrazeneca in a research note on Monday, June 8th. Sanford C. Bernstein reaffirmed a “buy” rating on shares of Astrazeneca in a report on Monday, May 4th. Finally, TD Cowen reiterated a “buy” rating on shares of Astrazeneca in a research note on Wednesday, March 18th. Twelve equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Astrazeneca presently has a consensus rating of “Moderate Buy” and an average price target of $205.33.

Astrazeneca Stock Up 0.0%

Astrazeneca stock opened at $178.79 on Monday. The firm has a market cap of $277.28 billion, a price-to-earnings ratio of 26.85, a PEG ratio of 1.55 and a beta of 0.25. The stock has a fifty day simple moving average of $189.26 and a two-hundred day simple moving average of $186.07. Astrazeneca has a 12 month low of $137.23 and a 12 month high of $212.71. The company has a current ratio of 0.91, a quick ratio of 0.71 and a debt-to-equity ratio of 0.52.

Institutional Trading of Astrazeneca

Several large investors have recently modified their holdings of AZN. Amundi grew its holdings in shares of Astrazeneca by 146,574.4% in the first quarter. Amundi now owns 15,386,149 shares of the company’s stock worth $3,034,456,000 after acquiring an additional 15,375,659 shares during the period. Janus Henderson Group PLC grew its holdings in shares of Astrazeneca by 889.9% in the first quarter. Janus Henderson Group PLC now owns 11,949,424 shares of the company’s stock worth $2,319,947,000 after acquiring an additional 10,742,268 shares during the period. Rathbones Group PLC grew its holdings in shares of Astrazeneca by 106,772.0% in the first quarter. Rathbones Group PLC now owns 8,054,943 shares of the company’s stock worth $1,560,419,000 after acquiring an additional 8,047,406 shares during the period. Royal Bank of Canada grew its holdings in shares of Astrazeneca by 208.6% in the first quarter. Royal Bank of Canada now owns 10,386,455 shares of the company’s stock worth $2,048,417,000 after acquiring an additional 7,021,126 shares during the period. Finally, Swiss National Bank bought a new stake in shares of Astrazeneca in the first quarter worth $1,202,714,000. Institutional investors own 20.35% of the company’s stock.

Astrazeneca Company Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.